SCHEMBL22314913

SCHEMBL22314913

O=c1oc2ncc(-c3ccc(OC(F)(F)F)cc3)cc2n1Cc1ncccn1

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SCN5A Q14524 4/20 0.48
SCN1A P35498 1/20 0.48
SCN4A P35499 1/20 0.48
KCNH2 Q12809 1/20 0.48
SCN9A Q15858 1/20 0.48
SCN2A Q99250 1/20 0.48
SCN3A Q9NY46 1/20 0.48
SCN8A Q9UQD0 1/20 0.48
SCN10A Q9Y5Y9 1/20 0.48
GRIN1 Q05586 8/20 0.45
GRIN2B Q13224 8/20 0.45
TNIK Q9UKE5 1/20 0.45
CA12 O43570 1/20 0.43
CA9 Q16790 1/20 0.43
CHRM5 P08912 1/20 0.39
CCNT1 O60563 1/20 0.38
CCNA2 P20248 1/20 0.38
CDK2 P24941 1/20 0.38
CDK9 P50750 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22314481 0.90 SCN5A (0.43) SCN5ASCN1ASCN4AKCNH2SCN9A
SCHEMBL22314553 0.87 TNIK (0.51) GRIN1GRIN2BTNIKCA12CA9
SCHEMBL22314911 0.86 SCN5A (0.52) SCN5ASCN1ASCN4AKCNH2SCN9A
SCHEMBL22314549 0.84 CA12 (0.44) SCN5ASCN9AGRIN1GRIN2BTNIK
SCHEMBL22314476 0.84 CA12 (0.44) SCN5ASCN9AGRIN1GRIN2BTNIK
SCHEMBL25865023 0.83 CA12 (0.42) SCN5ASCN9AGRIN1GRIN2BTNIK
SCHEMBL22314906 0.78 CA12 (0.46) SCN5ASCN9ASCN10AGRIN1GRIN2B
SCHEMBL22314557 0.76 SCN5A (0.46) SCN5ASCN1ASCN4AKCNH2SCN9A
SCHEMBL22314897 0.76 CA12 (0.44) SCN5ASCN10ACA12CA9
SCHEMBL25869414 0.75 MET (0.42) SCN5ASCN1ASCN4AKCNH2SCN9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230219938-A1 COMPOUNDS AND THEIR METHODS OF USE PRAXIS PREC MEDICINES INC (US) 2023-07-13 US disclosed
US-20230219938-A1 COMPOUNDS AND THEIR METHODS OF USE PRAXIS PREC MEDICINES INC (US) 2023-07-13 US disclosed
US-20200247793-A1 COMPOUNDS AND THEIR METHODS OF USE PRAXIS PRECISION MEDICINES, INC. (US) 2020-08-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200247793-A1 COMPOUNDS AND THEIR METHODS OF USE SCN1A, SCN3A, SCN1B SCN5A 8/4885SCN1A 1/4885SCN4A 29/4885
US-20230219938-A1 COMPOUNDS AND THEIR METHODS OF USE SCN1A, SCN3A, SCN1B SCN5A 8/4885SCN1A 1/4885SCN4A 29/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.